The FDA fast-tracked the application for a synthetic CBD drug intended to treat behavioral symptoms Fragile X syndrome, a rare genetic condition. The drug could also potentially be used to treat autism spectrum disorders. The drug is being developed by Pennsylvania biotech company Zynerba.
Philly.com
Quick Hit
- A House Committee called for relaxing barriers to MED and kratom research.
Marijuana Moment
